{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:07:40Z","timestamp":1788934060631,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Second-generation antipsychotics (SGAs) are widely utilized as first-line agents for several pediatric psychiatric and neurodevelopmental conditions, raising critical safety concerns. Although their cardiometabolic risks are well recognized, evidence on their long-term evolution in routine pediatric clinical practice remains limited. This study investigated the longitudinal cardiometabolic trajectories associated with SGA treatment in a real-world pediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, naturalistic, multicenter observational study, 82 children and adolescents initiating SGA treatment were followed for up to 24 months. Anthropometric, metabolic, and cardiovascular parameters were assessed longitudinally, and linear mixed-effects models were used to evaluate time-dependent changes and differences between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Retention rates and a low incidence of adverse event-related discontinuations suggested acceptable overall tolerability. Longitudinal analysis revealed significant increases in BMI, insulin and HOMA-IR whereas aggregate cardiovascular parameters did not exhibit statistically significant changes. Risperidone was associated with greater increases in waist circumference, prolactin, total cholesterol and ALT levels compared with aripiprazole. Furthermore, patients with Autism (ASD) exhibited significantly greater increases in BMI, waist circumference, and systolic blood pressure compared to non-ASD youth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While demonstrating an acceptable tolerability profile, risperidone and aripiprazole were associated with different cardiometabolic and endocrine variations over a 24-month period in this real-world pediatric cohort. These findings should be interpreted within the context of the study\u2019s observational nature and of potential confounding factors (e.g., unmeasured dietary, physical activity, and pubertal factors), highlighting the clinical necessity of longitudinal monitoring in children and adolescent patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1940707","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:58:50Z","timestamp":1788933530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal cardiometabolic trajectories in children and adolescents in therapy with second-generation antipsychotics: a real-world multicenter study"],"prefix":"10.3389","volume":"17","author":[{"given":"Grazia Maria Giovanna","family":"Pastorino","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University Magna Graecia of Catanzaro","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Salerno","place":["Baronissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Donadio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Salerno","place":["Baronissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Mungo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Magna Graecia of Catanzaro","place":["Catanzaro, Italy"]},{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Felicia","family":"Operto","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Magna Graecia of Catanzaro","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00404-7","article-title":"Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000-19 primary care data","volume":"10","author":"Radoj\u010di\u0107","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2025-302455","article-title":"Trends in antipsychotic drug utilisation and indication in the paediatric population: a nationwide cohort study in Sweden","volume":"29","author":"Kamgang","year":"2026","journal-title":"BMJ Ment Health"},{"key":"B3","volume-title":"First- and second-generation antipsychotics in children and young adults: systematic review update","author":"Pillay","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-014-0631-y","article-title":"Recent international trends in psychotropic medication prescriptions for children and adolescents","volume":"24","author":"Steinhausen","year":"2015","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaac.2009.09.003","article-title":"Trends in antipsychotic drug use by very young, privately insured children","volume":"49","author":"Olfson","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-5337808\/v1","article-title":"Trends in antipsychotic treatment of children and adolescents in Israel from post-mental health reform to post-COVID19 pandemic (2015-2023)","volume":"34","author":"Nega","year":"2025","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.7965","article-title":"Psychotropic medication prescribing for children and adolescents after the onset of the COVID-19 pandemic","volume":"7","author":"Valtuille","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5694\/mja2.51948","article-title":"Dispensing of psychotropic medications to Australian children and adolescents before and during the COVID-19 pandemic, 2013-2021: a retrospective cohort study","volume":"219","author":"Wood","year":"2023","journal-title":"Med J Aust"},{"key":"B9","volume-title":"Rapporto Osmed 2024","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo-controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2023.04.018","article-title":"Umbrella review: association between antipsychotic drugs and metabolic syndrome hallmarks in children and adolescents","volume":"63","author":"Carnovale","year":"2024","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-025-02771-0","article-title":"Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence","volume":"34","author":"Radha Krishnan","year":"2025","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174012","article-title":"Systematic review and meta-analysis of weight gain and metabolic changes in children and adolescents using second-generation antipsychotics","volume":"251","author":"Collares","year":"2025","journal-title":"Pharmacol Biochem Behav"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment: pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1010112","article-title":"Childhood adiposity, adult adiposity, and cardiovascular risk factors","volume":"365","author":"Juonala","year":"2011","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/16.9.581","article-title":"Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B19","volume-title":"Psychosis and Schizophrenia in Children and Young People: Recognition and Management","year":"2016"},{"key":"B20","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0016-6","article-title":"Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Almandil","year":"2013","journal-title":"Paediatr Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111349","article-title":"Impact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study","volume":"138","author":"Wada","year":"2025","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s78977","article-title":"Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Kishi","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4292\/wjgpt.v8.i1.26","article-title":"Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity","volume":"8","author":"Telles-Correia","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1940707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:58:52Z","timestamp":1788933532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1940707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":28,"alternative-id":["10.3389\/fpsyt.2026.1940707"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1940707","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1940707"}}